Oesity is a major global health problem. However, current therapeutic strategies for obesity are limited. Obesity results from an imbalance between ener-
gy intake and energy expenditure, and the treatment of obesity is based on the correction of this metabolic imbalance. Antiobesity drugs can shift this balance in a a>}~ o~ favorable way by reducing food intake, altering metabolism, and by increasing energy expenditure. There is a growing consensus that pharmacotherapy is appropriate olaj t} UJ n} o 011q-_71 ~LIH) (ener-for many individuals who are unable to lose weight through less intensive measures. However, side effects may ensue phamacotherapy for obesity. Only two drugs´ expenditure)4} a(intake)~(sbutramine and orlistat) are currently approved for the longterm treatment of _ tA~= L 7Aq os ~lv}~
obesity. Sibutramine inhibits the reuptake of serotonin and norepinephrine. Orlistat works by blocking the pancreatic lipase. However, phamarcotherapy may not be the o L AJ o1
ultimate resolution for obesity management, Because the underlying pathophysiology in each individual varies in many aspects, it is recommended to provide individuali- -fl´Mz ~i(reducing food intake)zed and tailored medication in addition to other antiobesity supportive treatments.
|